NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVBXXXX and the CUSIP is 63937X103. A total of 87 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q4 2014. The put-call ratio across all filers is 205.18 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $0 | – | 2,504 | 0.0% | 0.00% | – |
| Q4 2018 | $0 | -100.0% | 2,504 | 0.0% | 0.00% | – |
| Q3 2018 | $1,000 | 0.0% | 2,504 | 0.0% | 0.00% | – |
| Q2 2018 | $1,000 | 0.0% | 2,504 | -3.8% | 0.00% | – |
| Q1 2018 | $1,000 | -50.0% | 2,604 | -61.2% | 0.00% | – |
| Q4 2017 | $2,000 | -50.0% | 6,704 | -37.4% | 0.00% | – |
| Q3 2017 | $4,000 | -20.0% | 10,704 | +0.8% | 0.00% | – |
| Q2 2017 | $5,000 | -16.7% | 10,623 | +0.2% | 0.00% | – |
| Q1 2017 | $6,000 | -14.3% | 10,600 | 0.0% | 0.00% | – |
| Q4 2016 | $7,000 | -30.0% | 10,600 | 0.0% | 0.00% | – |
| Q3 2016 | $10,000 | +66.7% | 10,600 | 0.0% | 0.00% | – |
| Q2 2016 | $6,000 | -40.0% | 10,600 | 0.0% | 0.00% | – |
| Q1 2016 | $10,000 | -91.5% | 10,600 | -88.0% | 0.00% | – |
| Q4 2015 | $118,000 | +195.0% | 88,345 | +400.8% | 0.00% | – |
| Q3 2015 | $40,000 | +25.0% | 17,642 | -10.2% | 0.00% | – |
| Q2 2015 | $32,000 | +6.7% | 19,651 | +3.2% | 0.00% | – |
| Q1 2015 | $30,000 | +50.0% | 19,039 | +79.6% | 0.00% | – |
| Q4 2014 | $20,000 | +81.8% | 10,600 | +23.3% | 0.00% | – |
| Q3 2014 | $11,000 | -15.4% | 8,600 | -2.3% | 0.00% | – |
| Q2 2014 | $13,000 | -64.9% | 8,800 | -55.6% | 0.00% | – |
| Q1 2014 | $37,000 | +117.6% | 19,823 | +141.7% | 0.00% | – |
| Q4 2013 | $17,000 | -93.3% | 8,200 | -91.5% | 0.00% | – |
| Q3 2013 | $255,000 | +507.1% | 96,269 | +509.0% | 0.00% | – |
| Q2 2013 | $42,000 | – | 15,807 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |